Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2022 Filed Feb 18, 2022 01:00 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
GrantStock Option (Right to Buy) · Derivative | 21,029 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002661 · doc4.xml · derivative · entry 5 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,029 Underlying: Common Stock · 21,029 shares Expires 2032-02-16 F5 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:00 UTC |
Brown Vance RSVP, GC and Corp. Secretary
|
GrantRestricted Stock Units · Derivative | 7,354 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002661 · doc4.xml · derivative · entry 4 Brown Vance R · CIK 0001868243 · SVP, GC and Corp. Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,354 Underlying: Common Stock · 7,354 shares Expires 2026-02-16 F3 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F4 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F4 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:03 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
GrantStock Option (Right to Buy) · Derivative | 29,117 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002663 · doc4.xml · derivative · entry 6 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,117 Underlying: Common Stock · 29,117 shares Expires 2032-02-16 F6 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 01:03 UTC |
Butcher Arthur CEVP&Pres, Asia Pacific
|
GrantRestricted Stock Units · Derivative | 10,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002663 · doc4.xml · derivative · entry 5 Butcher Arthur C · CIK 0001678249 · EVP&Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,183 Underlying: Common Stock · 10,183 shares Expires 2026-02-16 F4 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:57 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 12,187 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001225208-22-002658 · doc4.xml · derivative · entry 9 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,187 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F9 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:57 UTC |
Brennan Daniel J.EVP and CFO
|
GrantStock Option (Right to Buy) · Derivative | 48,529 | $0.00 Strike: $44.19 | $0.00 |
DisclosureSEC source: 0001225208-22-002658 · doc4.xml · derivative · entry 8 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,529 Underlying: Common Stock · 48,529 shares Expires 2032-02-16 F8 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:57 UTC |
Brennan Daniel J.EVP and CFO
|
GrantRestricted Stock Units · Derivative | 16,972 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002658 · doc4.xml · derivative · entry 7 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,972 Underlying: Common Stock · 16,972 shares Expires 2026-02-16 F6 · derivative.exercise_price: Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F7 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. F7 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:57 UTC |
Brennan Daniel J.EVP and CFO
|
SaleCommon Stock | 12,187 | $43.70 | $532,580.43 |
DisclosureSEC source: 0001225208-22-002658 · doc4.xml · nonDerivative · entry 5 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,177 F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.50 to $43.84, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 00:57 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionCommon Stock | 12,187 | $6.28 | $76,534.36 |
DisclosureSEC source: 0001225208-22-002658 · doc4.xml · nonDerivative · entry 4 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:31 UTC |
Olson ScottSVP & Pres, CRM, Diagnostics
|
Exercise / conversionDeferred Stock Units · Derivative | 1,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002683 · doc4.xml · derivative · entry 3 Olson Scott · CIK 0001816850 · SVP & Pres, CRM, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,292 Underlying: Common Stock · 1,292 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:31 UTC |
Olson ScottSVP & Pres, CRM, Diagnostics
|
Tax withholdingCommon Stock | 707 | $44.01 | $31,115.07 |
DisclosureSEC source: 0001225208-22-002683 · doc4.xml · nonDerivative · entry 2 Olson Scott · CIK 0001816850 · SVP & Pres, CRM, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,844 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:31 UTC |
Olson ScottSVP & Pres, CRM, Diagnostics
|
Exercise / conversionCommon Stock | 1,292 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002683 · doc4.xml · nonDerivative · entry 1 Olson Scott · CIK 0001816850 · SVP & Pres, CRM, Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:42 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionDeferred Stock Units · Derivative | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002703 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,846 Underlying: Common Stock · 1,846 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:42 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Tax withholdingCommon Stock | 1,038 | $44.01 | $45,682.38 |
DisclosureSEC source: 0001225208-22-002703 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,639.99 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:42 UTC |
Thepaut Eric Francis YvesEVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionCommon Stock | 1,846 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002703 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · EVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,677.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:38 UTC |
Sorenson John BradleySVP, Global Supply Chain
|
Exercise / conversionDeferred Stock Units · Derivative | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002701 · doc4.xml · derivative · entry 4 Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200 Underlying: Common Stock · 1,200 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:38 UTC |
Sorenson John BradleySVP, Global Supply Chain
|
Tax withholdingCommon Stock | 368 | $44.01 | $16,195.68 |
DisclosureSEC source: 0001225208-22-002701 · doc4.xml · nonDerivative · entry 3 Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,579 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:38 UTC |
Sorenson John BradleySVP, Global Supply Chain
|
Exercise / conversionCommon Stock | 1,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002701 · doc4.xml · nonDerivative · entry 2 Sorenson John Bradley · CIK 0001629277 · SVP, Global Supply Chain 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:37 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
Exercise / conversionDeferred Stock Units · Derivative | 1,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002699 · doc4.xml · derivative · entry 3 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,108 Underlying: Common Stock · 1,108 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:37 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
Tax withholdingCommon Stock | 388 | $44.01 | $17,075.88 |
DisclosureSEC source: 0001225208-22-002699 · doc4.xml · nonDerivative · entry 2 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,862 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:37 UTC |
Scanlon MeghanSVP,Pres,Urology Pelvic Health
|
Exercise / conversionCommon Stock | 1,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002699 · doc4.xml · nonDerivative · entry 1 Scanlon Meghan · CIK 0001801586 · SVP,Pres,Urology Pelvic Health 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:34 UTC |
Pierce David AEVP Pres MedSurg
|
Exercise / conversionDeferred Stock Units · Derivative | 2,769 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002694 · doc4.xml · derivative · entry 4 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,769 Underlying: Common Stock · 2,769 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:34 UTC |
Pierce David AEVP Pres MedSurg
|
Tax withholdingCommon Stock | 813 | $44.01 | $35,780.13 |
DisclosureSEC source: 0001225208-22-002694 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,956 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:34 UTC |
Pierce David AEVP Pres MedSurg
|
Exercise / conversionCommon Stock | 2,769 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002694 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,769 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:25 UTC |
Monson JonathanVP, Global Controller and CAO
|
Exercise / conversionDeferred Stock Units · Derivative | 738 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002679 · doc4.xml · derivative · entry 3 Monson Jonathan · CIK 0001779170 · VP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 739 Underlying: Common Stock · 738 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:25 UTC |
Monson JonathanVP, Global Controller and CAO
|
Tax withholdingCommon Stock | 259 | $44.01 | $11,398.59 |
DisclosureSEC source: 0001225208-22-002679 · doc4.xml · nonDerivative · entry 2 Monson Jonathan · CIK 0001779170 · VP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,222 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:25 UTC |
Monson JonathanVP, Global Controller and CAO
|
Exercise / conversionCommon Stock | 738 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002679 · doc4.xml · nonDerivative · entry 1 Monson Jonathan · CIK 0001779170 · VP, Global Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:28 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionDeferred Stock Units · Derivative | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002681 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,661 Underlying: Common Stock · 1,661 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:28 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Tax withholdingCommon Stock | 575 | $44.01 | $25,305.75 |
DisclosureSEC source: 0001225208-22-002681 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,492 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:28 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionCommon Stock | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002681 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,067 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:24 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Exercise / conversionDeferred Stock Units · Derivative | 2,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002677 · doc4.xml · derivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,031 Underlying: Common Stock · 2,030 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:24 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Tax withholdingCommon Stock | 622 | $44.01 | $27,374.22 |
DisclosureSEC source: 0001225208-22-002677 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,561 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:24 UTC |
Mirviss Jeffrey B.EVP&Pres, Periph Intervent
|
Exercise / conversionCommon Stock | 2,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002677 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · EVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:21 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
Exercise / conversionDeferred Stock Units · Derivative | 1,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002675 · doc4.xml · derivative · entry 3 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,108 Underlying: Common Stock · 1,108 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:21 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
Tax withholdingCommon Stock | 326 | $44.01 | $14,347.26 |
DisclosureSEC source: 0001225208-22-002675 · doc4.xml · nonDerivative · entry 2 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,621 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:21 UTC |
Meredith Ian TEVP Global Chief Med Officer
|
Exercise / conversionCommon Stock | 1,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002675 · doc4.xml · nonDerivative · entry 1 Meredith Ian T · CIK 0001693920 · EVP Global Chief Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,947 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:19 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionDeferred Stock Units · Derivative | 18,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002673 · doc4.xml · derivative · entry 3 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,457 Underlying: Common Stock · 18,457 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:19 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Tax withholdingCommon Stock | 8,186 | $44.01 | $360,265.86 |
DisclosureSEC source: 0001225208-22-002673 · doc4.xml · nonDerivative · entry 2 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,094,283 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:19 UTC |
Mahoney Michael FDirector · Chairman, President & CEO
|
Exercise / conversionCommon Stock | 18,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002673 · doc4.xml · nonDerivative · entry 1 Mahoney Michael F · CIK 0001533022 · Director · Chairman, President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,102,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:15 UTC |
Mackey Edward FEVP, Operations
|
Exercise / conversionDeferred Stock Units · Derivative | 2,769 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002671 · doc4.xml · derivative · entry 3 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,769 Underlying: Common Stock · 2,769 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:15 UTC |
Mackey Edward FEVP, Operations
|
Tax withholdingCommon Stock | 813 | $44.01 | $35,780.13 |
DisclosureSEC source: 0001225208-22-002671 · doc4.xml · nonDerivative · entry 2 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,434 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:15 UTC |
Mackey Edward FEVP, Operations
|
Exercise / conversionCommon Stock | 2,769 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002671 · doc4.xml · nonDerivative · entry 1 Mackey Edward F · CIK 0001632900 · EVP, Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:12 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Cardiology
|
Exercise / conversionDeferred Stock Units · Derivative | 4,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002669 · doc4.xml · derivative · entry 6 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,615 Underlying: Common Stock · 4,614 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F5 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F5 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:12 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Cardiology
|
Tax withholdingCommon Stock | 2,278 | $44.01 | $100,254.78 |
DisclosureSEC source: 0001225208-22-002669 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,088 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:12 UTC |
Fitzgerald Joseph MichaelEVP & Pres, Cardiology
|
Exercise / conversionCommon Stock | 4,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002669 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & Pres, Cardiology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:06 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionDeferred Stock Units · Derivative | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002665 · doc4.xml · derivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,661 Underlying: Common Stock · 1,661 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:06 UTC |
Carruthers WendySVP, Human Resources
|
Tax withholdingCommon Stock | 488 | $44.01 | $21,476.88 |
DisclosureSEC source: 0001225208-22-002665 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,564 Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:06 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionCommon Stock | 1,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002665 · doc4.xml · nonDerivative · entry 1 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:09 UTC |
Eddy Jodi EuerleSVP, Chief Info & Digital Off.
|
Exercise / conversionDeferred Stock Units · Derivative | 923 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-002667 · doc4.xml · derivative · entry 3 Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 925 Underlying: Common Stock · 923 shares Expires 2023-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:09 UTC |
Eddy Jodi EuerleSVP, Chief Info & Digital Off.
|
Tax withholdingCommon Stock | 272 | $44.01 | $11,970.72 |
DisclosureSEC source: 0001225208-22-002667 · doc4.xml · nonDerivative · entry 2 Eddy Jodi Euerle · CIK 0001734900 · SVP, Chief Info & Digital Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,531 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.